Spectral AI (MDAI) announced immediate non-dilutive funding from BARDA, adding to its contract's total potential value of $150 million. This funding supports product development and FDA clearance efforts, positively impacting investor sentiment and pushing MDAI shares up by 8.33%.
MDAI's DeepView AI system aids burn healing assessments using multi-spectral imaging. The device has FDA Breakthrough Device Designation, enhancing its market potential.
- Spectral AI Inc (NASDAQ:MDAI) has been added to the Russell Microcap Index. - Inclusion in the index may lead to increased visibility and investor interest. Price Impact Rating: Bullish Impact Horizon Rating: Short-term Type: Corporate Developments